Gout causes swelling, stiffness, and intense joint discomfort, resulting in a painful and debilitating condition. Individuals familiar with Uloric, a medication aimed at reducing uric acid levels and alleviating gout symptoms, may wish to be informed about recent studies that associate it with an elevated risk of heart disease and other cardiovascular problems. If you or your loved one has experienced heart-related complications after taking Uloric, you may be eligible for compensation via a Uloric lawsuit. It is crucial to work with an experienced Uloric lawsuit lawyer who can actively guide you through the legal process and help you achieve a favorable outcome, ensuring justice is served.
Gout and Uloric: Potential Risks and Warnings
Millions of people suffer from gout, a form of arthritis caused by the accumulation of uric acid in one or more joints. This buildup can lead to sudden pain, swelling, and redness. Since 2009, Uloric, also known as febuxostat, has been a commonly prescribed medication for gout treatment. However, recent research suggests a potential link between Uloric and an increased risk of death. In February 2019, the FDA issued a Black Box warning on all Uloric prescriptions, highlighting the potentially life-threatening risks associated with this drug.
Increased Risk of Heart Complications
Multiple studies have demonstrated that Uloric potentially raises the risk of heart complications, including heart attack, stroke, and heart-related mortality. Notably, the FDA conducted research comparing Uloric to Allopurinol, a commonly prescribed gout medication, and found a higher mortality risk associated with Uloric usage. Consequently, the FDA mandated Takeda Pharmaceuticals, the manufacturer of Uloric, to perform a safety study and include the Black Box warning on all Uloric prescriptions.
The Medication’s Mechanism of Action
The medication lowers uric acid levels in the body, reducing protective factors in the blood that aid in preventing heart complications. This poses particular concern as Uloric can also induce liver problems and abnormal heart rhythms, further elevating the risk of mortality in patients who use the medication.
FDA Rejection of Uloric and Cardiovascular Risks
First Rejection and Increased Risk:
In 2005 and 2006, the FDA rejected Uloric initially due to clinical trials that showed an increased risk of cardiovascular thromboembolic events with febuxostat. Such events, including strokes and blood clots, have the potential to be life-threatening. Before approving the drug, the FDA mandated additional data to ensure patient safety.
Safety Trial and FDA Approval:
Takeda and Abbott Laboratories, the manufacturers of Uloric, conducted a safety trial and presented additional information on cardiovascular risks, ultimately leading to the FDA’s approval in 2009. However, the FDA approved it with a warning label addressing the heightened cardiovascular risk. This precaution aimed to ensure patient awareness and facilitate informed decision-making.
Testing and Approval Process:
The previous rejections of Uloric suggest potential concerns about the adequacy of drug testing before FDA approval. Perhaps conducting more extensive testing could have identified the increased risk of thromboembolic events and prevented the initial rejections. These concerns prompt a discussion about the necessity for implementing more rigorous requirements in drug testing during FDA approval processes. Why didn’t Uloric undergo more extensive testing before the FDA approved it?
Hundreds of lawsuits filed
The Northern District of Georgia currently has 850 pending Uloric lawsuits, which the Judicial Panel on Multidistrict Litigation has consolidated into an MDL (multidistrict litigation). This consolidation streamlines the legal process for cases involving similar allegations of harm caused by the medication.
Allegations of wrongful death and injuries
Many Uloric lawsuits allege wrongful death or serious injuries, including heart attacks, strokes, and myocardial infarctions. These injuries are connected to increased uric acid levels in the body caused by uric acid. Consequently, urate crystals can accumulate in the joints and organs.
Plaintiffs may be entitled to compensation.
You may potentially be eligible for compensation if you or a loved one has experienced harm from using Uloric. Additionally, compensation can assist in covering medical expenses, lost wages, and other damages that may arise from injury or death. It is paramount to consult with an experienced Uloric lawsuit attorney to review your case and fully explore your legal options.
Statute of limitations
When considering a Uloric lawsuit, it is crucial to remember that there is a statute of limitations deadline for filing. Additionally, this deadline may vary by state, typically ranging from one to three years from the injury or discovery thereof. Therefore, failing to meet this deadline may lead to case dismissal, necessitating prompt action.
Contact a GT&B Uloric Lawsuit Lawyer.
Prescribers commonly recommend Uloric as a medication to alleviate gout symptoms. However, recent FDA warnings have shed light on severe risks associated with its usage, including heart complications and heightened mortality rates. At Gallon, Takacs & Boissoneault, we firmly believe in providing patients with comprehensive information on medication risks. It is crucial to have a thorough discussion with your doctor regarding the potential benefits and drawbacks of Uloric before initiating treatment. If you have encountered severe adverse effects after taking Uloric, we urge you to contact us for a complimentary case evaluation. A knowledgeable Uloric lawsuit lawyer at GT&B will guide you in understanding your legal rights and available options. Do not hesitate to contact us today at 419-843-6663 or by utilizing our online contact form for a complimentary case evaluation.
